News
Permanent Committee for the Drafting of the Egyptian Pharmacopoeia Holds Its Seventh Meeting
The Permanent Committee for the Drafting of the Egyptian Pharmacopoeia convened its seventh session at the headquarters of the Egyptian Drug Authority (EDA) in Agouza to continue discussions on the mechanisms governing the development of the Egyptian Pharmacopoeia.
The meeting was chaired by Dr. Ayman El-Khatib, Vice President of the Egyptian Drug Authority and Chairman of the Permanent Committee, and was attended by Dr. Mohamed Awad Tag El-Din, Advisor to the President of the Republic for Health and Prevention Affairs, and Counselor Mohamed El-Demerdash, Vice President of the State Council and Legal Advisor to the Egyptian Drug Authority.
During the meeting, participants reviewed the content and structure of the Egyptian Pharmacopoeia's official website. They also discussed recent progress achieved in the development process, including the proposed content of the general chapters and general notices of the Egyptian Pharmacopoeia, in addition to nominations for the Expert Committee representing various scientific disciplines.
The Committee further reviewed the participation of the Egyptian Pharmacopoeia in the First Africa Health ExCon, during which emphasis was placed on the vision and mission of the Egyptian Pharmacopoeia in promoting and protecting public health through ensuring the quality of medicinal products.
In addition, discussions addressed opportunities for collaboration with leading international pharmacopoeias to facilitate knowledge transfer and the exchange of expertise. Particular attention was given to the technical and legal considerations associated with the terms and conditions governing the reproduction and citation rights of the United States Pharmacopeia (USP).
Participants also reviewed the latest developments concerning the training program to be delivered by the United States Pharmacopeia, which was scheduled to take place in July. The program was intended to strengthen scientific and technical capabilities and support the development of a national pharmacopoeial framework aligned with internationally recognized standards.